WordNet

limit, block, or decrease the action or function of; "inhibit the action of the enzyme"; "inhibit the rate of a chemical reaction"
control and refrain from showing; of emotions, desires, impulses, or behavior (同)bottle up, suppress
limit the range or extent of; "Contact between the young was inhibited by strict social customs"
remove the bones from; "bone the turkey before roasting it" (同)debone
the porous calcified substance from which bones are made (同)osseous_tissue
consisting of or made up of bone; "a bony substance"; "the bony framework of the body"
a shade of white the color of bleached bones (同)ivory, pearl, off-white
rigid connective tissue that makes up the skeleton of vertebrates (同)os
having bones as specified; "his lanky long-boned body"
having had the bones removed; "a boneless rib roast"; "a boned (or deboned) fish" (同)deboned
a substance that retards or stops an activity
the organic process in which the substance of some differentiated structure that has been produced by the body undergoes lysis and assimilation (同)reabsorption

PrepTutorEJDIC

〈感情・欲望・行動・作用など〉‘を'抑制する / (…しないように)〈人〉‘を'抑制する,妨げる《+『名』+『from』+『名』(do『ing』)》
〈C〉骨 / 〈U〉骨を作っている物質,骨質 / 《複数形で》骨格;死骸(がい) / 〈魚など〉‘の'骨を取る
(魚など)骨を取り除いた / (衣服が)(コルセットなどで)骨で張りをつけた[ような]
抑制する人(物) / 化学反応抑制剤

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 乳癌による骨転移のマネージメントにおける骨吸収抑制剤 osteoclast inhibitors in the management of bone metastases from breast cancer
2. 進行癌患者における骨修飾薬による薬剤療法のリスク risks of therapy with bone modifying agents in patients with advanced malignancy
3. アロマターゼ阻害剤による骨量減少の評価およびマネージメント evaluation and management of aromatase inhibitor induced bone loss
4. ビスホスホネートの薬理学 pharmacology of bisphosphonates
5. 骨代謝の生理学および生化学的マーカー bone physiology and biochemical markers of bone turnover

English Journal

OA10 Is a Novel p38alpha Mitogen-Activated Protein Kinase Inhibitor That Suppresses Osteoclast Differentiation and Bone Resorption.

Jiang T1, Qin A, Shao ZY, Tian B, Zhai ZJ, Li HW, Zhu ZA, Dai KR, Ming HZ, Yu YP, Jiang Q.Author information 1The Center of Diagnosis and Treatment for Joint Disease, Drum Tower Clinical Medical College of Nanjing Medical University, Jiangsu, P.R. China.AbstractIn search of anti-bone resorbing agents for the potential treatment of osteoporosis, we synthesized a novel compound Tert-butyl 4-(3-[1H-indole-2-carboxamido]benzoyl)piperazine-1-carboxylate (OA10) and found that OA10 is capable of inhibiting RANKL-mediated osteoclast formation and osteoclastic bone resorption in a dose-dependent manner. This biological effect is further supported by the fact that OA10 suppressed osteoclastic-specific gene expression, including tartrate-resistant acid phosphatase, cathepsin K receptor, and calcitonin receptor. Further molecular mechanism investigation revealed OA10 inhibited p38 phosphorylation, suppressed c-fos and NFATc1 expression without affecting NF-κB or JNK signaling pathways. Taken together, this study suggested that OA10 can inhibit osteoclastogenesis by suppressing p38-c-Fos-NFATc1 cascade. OA10 may be developed as a therapeutic drug for osteoclast-related osteolytic diseases. J. Cell. Biochem. 115: 959-966, 2014. © 2013 Wiley Periodicals, Inc.
Journal of cellular biochemistry.J Cell Biochem.2014 May;115(5):959-66. doi: 10.1002/jcb.24744.
In search of anti-bone resorbing agents for the potential treatment of osteoporosis, we synthesized a novel compound Tert-butyl 4-(3-[1H-indole-2-carboxamido]benzoyl)piperazine-1-carboxylate (OA10) and found that OA10 is capable of inhibiting RANKL-mediated osteoclast formation and osteoclastic bone
PMID 24357524

Role of bisphosphonates in postmenopausal women with breast cancer.

Gnant M.Author information Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna, Austria. Electronic address: michael.gnant@meduniwien.ac.at.AbstractData suggest that bisphosphonates protect bone health and may have anticancer activity in postmenopausal women during adjuvant breast cancer therapy. However, key questions remain surrounding the role of adjuvant bisphosphonates in breast cancer, including patient populations deriving benefit, timing/scheduling of therapy, and specific clinical benefits. PubMed, Embase, and San Antonio Breast Cancer Symposium databases provide study results that address these issues in postmenopausal women. Review of these data would aid physicians in providing optimal management of breast cancer in postmenopausal women. For example, recent data reinforce use of intravenous bisphosphonates concurrently with adjuvant endocrine therapy to ameliorate bone loss in recently postmenopausal or osteopenic postmenopausal women with early breast cancer. In contrast, clinical data for oral bisphosphonates have not provided support for using anti-osteoporosis doses in this setting, and the optimal dose is unclear. Additionally, current clinical data show improvements in disease outcomes with bisphosphonates in many studies, although not in all patient subsets. Strong support for the potential adjuvant anticancer benefits from bisphosphonates has been demonstrated in women with established menopause (i.e., very low circulating estrogen levels). Initiating bisphosphonates early and concomitantly with adjuvant therapy generally provided the greatest benefits. However, questions remain such as schedule of treatment and relative potency among the intravenous bisphosphonates and elucidation of the role of oral bisphosphonates, as well as ongoing studies that might provide clarification. This review addresses these controversies in the context of translational research, which may provide the rationale for ongoing studies and evolving treatment paradigms in this area.
Cancer treatment reviews.Cancer Treat Rev.2014 Apr;40(3):476-84. doi: 10.1016/j.ctrv.2013.07.003. Epub 2013 Jul 29.
Data suggest that bisphosphonates protect bone health and may have anticancer activity in postmenopausal women during adjuvant breast cancer therapy. However, key questions remain surrounding the role of adjuvant bisphosphonates in breast cancer, including patient populations deriving benefit, timin
PMID 23906846

Estrogen inhibits RANKL-induced osteoclastic differentiation by increasing the expression of TRPV5 channel.

Chen F1, Ouyang Y, Ye T, Ni B, Chen A.Author information 1Department of Orthopaedic Surgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.AbstractThe inhibitor effect of estrogen on osteoclasts differentiation is very important in the etiology of estrogen protecting the adult skeleton against bone loss. However, the precise molecular events underlying the effect of estrogen on osteoclasts differentiation are not known. Recent studies implicated an important role of transient receptor potential vanilloid 5 (TRPV5) in osteoclast differentiation and bone resorption. Furthermore, some studies have confirmed that estrogen is involved in the regulation of calcium ion (Ca(2+)) influx in many cells via TRPV5 channel. Therefore, we hypothesize that TRPV5 channel may be implicated in the process of estrogen-inhibited osteoclastogenesis and bone resorption. Western blot, quantitative real-time PCR, tartrate-resistant acid phosphatase (TRAP) staining, and pit formation assay were employed to investigate the role of TRPV5 in estrogen decreasing osteoclast differentiation and bone resorption. We found that the expression of TRPV5 is significantly down-regulated during estrogen deficiency-induced osteoclastogenesis. Furthermore, TRAP staining and pit formation assay showed that the depletion of TRPV5 significantly blocks the inhibitor effects of estrogen on osteoclasts differentiation and bone resorption activity. Further studies confirmed that estrogen regulates the expression of TRPV5 channel via estrogen receptor. Based on these results above, we can draw conclusion that TRPV5 may contribute to the process of estrogen-inhibited osteoclastogenesis and bone resorption activity.
Journal of cellular biochemistry.J Cell Biochem.2014 Apr;115(4):651-8. doi: 10.1002/jcb.24700.
The inhibitor effect of estrogen on osteoclasts differentiation is very important in the etiology of estrogen protecting the adult skeleton against bone loss. However, the precise molecular events underlying the effect of estrogen on osteoclasts differentiation are not known. Recent studies implicat
PMID 24150765

Japanese Journal

Genipin Inhibits RANKL-Induced Osteoclast Differentiation Through Proteasome-Mediated Degradation of c-Fos Protein and Suppression of NF-κB Activation

Hoon Lee Chang,Kwak Sung-Chul,Kim Ju-Young,Mee Oh Hyun,Chual Rho Mun,Yoon Kwon-Ha,Yoo Wan-Hee,Su Lee Myeung,Oh Jaemin
Journal of Pharmacological Sciences 124(3), 344-353, 2014
… Osteoclasts are responsible for bone resorption in bone-related disorders. … Genipin dose-dependently inhibited early stage RANKL-induced osteoclast differentiation in bone marrow macrophages (BMMs) during culture. … Interestingly, genipin markedly inhibited c-Fos protein expression in BMMs, which was reversed in the presence of the proteosome inhibitor MG-132. …
NAID 130003391489

Assessment of Alloxan-Induced Diabetic Rats as a Periodontal Disease Model Using a Selective Cyclooxygenase (COX)-2 Inhibitor

Nakahara Yutaka,Ozaki Kiyokazu,Sano Tomoya,Kodama Yasushi,Matsuura Tetsuro
Journal of Toxicologic Pathology 27(2), 123-129, 2014
… In this study, we evaluated the use of diabetic rats as a PD model by employing a selective COX-2 inhibitor reported to be effective against PD. … Gingivitis, marginal periodontitis and alveolar bone resorption were markedly enhanced along with dental caries in the AL group compared with the control group. … However, the COX-2 inhibitor had no effect on periodontal inflammation in the AL+Et group. …
NAID 130003391346

Chlorogenic Acid Inhibits Osteoclast Differentiation and Bone Resorption by Down-Regulation of Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Nuclear Factor of Activated T Cells c1 Expression

Kwak Sung Chul,Lee Cheol,Kim Ju-Young [他],Oh Hyun Mee,So Hong-Seob,Lee Myeung Su,Rho Mun Chual,Oh Jaemin
Biological and Pharmaceutical Bulletin 36(11), 1779-1786, 2013
… Excessive osteoclastic bone resorption plays a critical role in inflammation-induced bone loss such as rheumatoid arthritis and periodontal bone erosion. … Therefore, identification of osteoclast targeted-agents may be a therapeutic approach to the treatment of pathological bone loss. … In this study, we isolated chlorogenic acid (CGA) from fructus of Gardenia jasminoides to discover anti-bone resorptive agents. …
NAID 130003361551